Helus Pharma prices $50M share offering at $4.85 per share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Helus Pharma™ Announces US$50 Million Underwritten Offering
June 24, 2026 6:01 AM EDTNEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the Company or Helus Pharma), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (NSAs), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the Common Shares) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the Offering).
... More